The FGB-FM-ESO Joint International Conference 2025 on Innovation in Oncology: New Drugs and the Impact of Artificial Intelligence will take place on November 12-13, 2025, at Fondazione Prada, Godard Cinema, in Milan, Italy. This cutting-edge event will bring together leading experts in oncology, artificial intelligence, and drug development to explore the latest breakthroughs in cancer therapeutics, as well as the transformative potential of AI in clinical oncology.
Conference Overview
The two-day conference aims to foster collaboration between clinicians and researchers, offering a platform for knowledge exchange and innovation in cancer care. The event will showcase the latest advancements in oncology drugs and discuss how artificial intelligence (AI) is shaping the future of cancer diagnosis, treatment selection, and patient care.
This year, the conference also marks the 10th anniversary of the passing of Gianni Bonadonna, a pioneer in modern oncology. To honor his legacy, the Gianni Bonadonna Prize will be awarded to a young investigator who has made outstanding contributions to innovative therapies in oncology.
Key Topics and Sessions
- Emerging Paradigms in Drug Development (Session 1, November 12)
The conference will feature sessions on next-generation antibody-drug conjugates, cancer immunotherapy, and advancements in endocrine therapy for breast cancer. Experts will delve into T-cell engineering for solid tumors and other novel therapies, exploring how they are poised to change cancer treatment paradigms.
- The Diagnostic Revolution in Oncology and AI’s Role (Session 2, November 13)
One of the central themes will be the integration of artificial intelligence into oncology. Leading researchers will discuss the clinical utility of ctDNA for monitoring treatment response, radiomics for transforming imaging data into actionable insights, and the application of computational pathology for predicting patient responses. The event will explore AI’s potential in both early detection and predicting resistance mechanisms, key to improving outcomes in metastatic cancer.
- New Horizons in Oncology Drug Development (Session 3, November 13)
The conference will also focus on innovative drug development, including dose optimization and tumor-agnostic methods in early-phase clinical trials. Experts will discuss strategies to improve therapeutic indices and reduce costs through post-approval dose optimization and the rational development of drug combinations.
Practical Implementation and Collaboration
The Innovation in Oncology conference aims to bridge the gap between academic research and clinical practice, promoting collaboration between established researchers and emerging talent in the oncology field. It will also provide a platform for addressing the practical challenges of implementing these cutting-edge technologies and treatments in real-world clinical settings.
CME Accreditation and Registration
The conference is accredited by the European Accreditation Council for Continuing Medical Education (EACCME®), offering 8.5 European CME credits (ECMEC®s) for attendees. With only 180 spots available, attendance is limited and will be on a first-come, first-served basis.
The registration includes
- free entry,
- meals according to the program,
but travel and accommodation expenses will be the responsibility of the participants.
Faculty
Lubna Ahmad, CRUK, Cancer Research UK Cambridge Centre, Cambridge, UK
Giampaolo Bianchini, Ospedale San Raffaele, Dept. of Medical Oncology – O.U. Medicine 1Q-A, Milano, IT
Chiara Bonini, IRCCS Ospedale San Raffaele, Experimental hematology, Milano, IT
Irène Buvat, Institut Curie Paris, Director Laboratory of Translational Imaging in Oncology, Paris, FR
Raffaele Colombo, Zymeworks Inc, ADC Therapeutic Development, Vancouver, CA
Isaac Garcia-Murillas, The Institute of Cancer Research, Molecular Oncozlogy, London, UK
Hugo Horlings, Netherlands Cancer Institute, Netherlands Cancer Institute, Amsterdam, NL
Rinath Jeselsohn, Dana-Farber Cancer Institute, Dana-Farber Cancer Institute, Boston, US
Lajos Pusztai, Yale Cancer Center, Scientific Co-Director of the Center for Breast Cancer, New Haven, US
Mark J. Ratain, Cancer Research Center, The University of Chicago, Dept. of Medicine, Chicago, US
Vivek Subbiah, Sarah Cannon Research Institute (SCRI), Sarah Cannon Research Institute (SCRI), Nashville, Tennessee, US
Carlo Tacchetti, IRCCS Ospedale San Raffaele, IRCCS Ospedale San Raffaele, Milano, IT
Ian Tannock, Toronto, CA
Diego Tosi, Cancer Institute of Montpellier (ICM), Oncology, Montpellier, FR
Registration
Interested attendees can register online, and once confirmed, will receive additional details. For more information, please visit the official conference page.
Honoring Gianni Bonadonna
A highlight of the Innovation in Oncology conference will be the presentation of the Gianni Bonadonna Prize 2025. This prestigious award honors the memory of Gianni Bonadonna, one of the pioneers in modern oncology, particularly in the development of chemotherapy for breast cancer. The prize will be awarded to an outstanding young investigator who has made significant contributions to innovative therapies in oncology.
The award ceremony will take place at 16:45 on November 12,
followed by a presentation of the winner’s project, showcasing their groundbreaking work in cancer research.
This ceremony serves as a tribute to Bonadonna’s lasting impact on the field and encourages the next generation of oncologists to continue his legacy of excellence and innovation.
Get to know European School of Oncology’s future educational events here.
You can read more articles featuring ESO and Gianni Bonadonna on Oncodaily’s website.
Written by Sergey Badalyan, MD